Holen Sie sich die Stockscreener-App
1.35
0.75%
0.01
Handel nachbörslich:
1.35
Schlusskurs vom Vortag:
$1.34
Offen:
$1.34
24-Stunden-Volumen:
17,839
Relative Volume:
0.36
Marktkapitalisierung:
$4.93M
Einnahmen:
$3,000
Nettoeinkommen (Verlust:
$-5.16M
KGV:
-0.9552
EPS:
-1.4133
Netto-Cashflow:
$-5.43M
1W Leistung:
+7.14%
1M Leistung:
+0.00%
6M Leistung:
-69.93%
1J Leistung:
-80.18%
1-Tages-Spanne:
$1.30
$1.35
1-Wochen-Bereich:
$1.24
$1.41
52-Wochen-Spanne:
$1.16
$9.37
Pulmatrix Inc Stock (PULM) Company Profile
Firmenname
Pulmatrix Inc
Sektor
Branche
Telefon
(888) 355-4440
Adresse
945 CONCORD STREET, FRAMINGHAM, MA
Compare PULM vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PULM
Pulmatrix Inc
|
1.35 | 4.89M | 3,000 | -5.16M | -5.43M | -1.4133 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pulmatrix Inc Stock (PULM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-02-09 | Eingeleitet | H.C. Wainwright | Buy |
Pulmatrix Inc Aktie (PULM) Neueste Nachrichten
Pulmatrix Q2 2025 Earnings: Loss Per Share Widens Amidst No Revenue DisclosureSocial Trade Signals - Newser
PULM Technical Analysis | Trend, Signals & Chart Patterns | PULMATRIX INC (NASDAQ:PULM) - ChartMill
Pulmatrix Q2 2025 Earnings: Clinical-Stage Biotech Posts Net Loss of $0.42 per Share, Stock Rises 7.87%Community Buy Alerts - newser.com
Pulmatrix (PULM) Reports Predictable Q2 2025 — EPS $-0.42 On TargetTrading Community - Newser
Pulmatrix, Inc. Q1 2026 10-Q Report: Financial Results, Merger with Eos SENOLYTIX, and Going Concern Risks - Minichart
Pulmatrix Releases Q1 2026 Financial Results - AlphaStreet
Press Release: Pulmatrix Announces First Quarter 2026 Financial Results - Moomoo
Pulmatrix Announces Q1 2026 Financial Results and Merger Agreement with Eos SENOLYTIX - Minichart
PULM: Merger with Eos SENOLYTIX announced; Q1 net loss narrows, cash at $3.3M - TradingView
Pulmatrix, Inc. 1Q 2026: Net loss $(1.17M), EPS $(0.32) — 10-Q Summary - TradingView
Pulmatrix Q1 net loss narrows, clinical development on hold - TradingView
Pulmatrix reports Q1 2026 net loss $1.17M, cash $3.3M and announces merger agreement with Eos SENOLYTIX - TradingView
Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Pulmatrix (PULM) Q1 2026 shows tight cash, Eos merger and 94% pro forma dilution - Stock Titan
Pulmatrix (NASDAQ: PULM) Q1 loss, $1M raise and Eos merger plan - Stock Titan
TradingKey - TradingKey
Number of shareholders of Pulmatrix, Inc. – NASDAQ:PULM - TradingView
The hidden strength in Pulmatrix (PULM) most investors miss (Volatility Increases) 2026-05-08Attention Stocks - newser.com
The hidden strength in Pulmatrix (PULM) most investors miss (Risk Aversion) 2026-05-08Crowd Entry Points - newser.com
Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets - Quantisnow
Pulmatrix (PULM) Stock: Is It Losing Market Strength |Shared Buy Zones - Newser
Eos-backed investor takes 9.99% Pulmatrix (PULM) stake ahead merger - Stock Titan
PULM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pulmatrix, Inc. announced that it has received $1 million in funding - marketscreener.com
Pulmatrix closes $1M preferred stock placement with Eos affiliate - Investing.com
Pulmatrix Closes $1M Series B Preferred Stock Investment at $2.20 per Share as Part of Planned Merger with Eos SENOLYTIX 1 - Minichart
Pulmatrix announces closing of preferred stock transaction as part of planned merger - marketscreener.com
Pulmatrix Announces Closing Of Preferred Stock Transaction As Part Of Planned Merger - TradingView
Pulmatrix closes $1M preferred stock placement with Eos affiliate By Investing.com - Investing.com Canada
Pulmatrix Raises $1M in Preferred Stock Financing - TipRanks
Pulmatrix closes $1M Series B preferred private placement tied to planned merger - TradingView
Pulmatrix (NASDAQ: PULM) closes $1M Series B preferred tied to Eos merger - Stock Titan
Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger - PR Newswire
Pulmatrix (PULM) Stock: Why Working Capital (Trades Higher) 2026-04-20Fibonacci Analysis - Cổng thông tin điện tử tỉnh Lào Cai
PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders - The AI Journal
Momentum Shift: Is Pulmatrix Inc in a consolidation phase2026 Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
If You Invested $1,000 in Pulmatrix (PULM) - Stock Titan
Stock Recap: Will Pulmatrix Inc benefit from current market trends2026 Historical Comparison & Verified High Yield Trade Plans - baoquankhu1.vn
Gains Report: Will Pulmatrix Inc benefit from seasonality2026 Technical Patterns & Smart Money Movement Tracker - baoquankhu1.vn
Is Pulmatrix (PULM) Stock Good for Beginners | Price at $1.26, Down 4.55%Community Chart Signals - Newser
Is Pulmatrix (PULM) Stock Good for Long Term | Price at $1.35, Up 3.05%Overnight Profile - Newser
PULM Stock Analysis: Pulmatrix Inc. Biotech At $1.31 Post Minor Daily Decline - Newser
FOMO Trade: Will Pulmatrix Inc benefit from current market trendsQuarterly Trade Review & Consistent Income Trade Recommendations - baoquankhu1.vn
FRA:2PU PB Ratio: 1.34 — 15% Above Median - GuruFocus
Pulmatrix and Eos SENOLYTIX Announce $19 Million Merger to Advance Mitochondrial Therapies - Global Legal Chronicle
Pulmatrix shares dive as privately-held pharma company chooses to merge with Gyre Therapeutics instead - MSN
Ideas Watch: Is Pulmatrix Inc in a consolidation phaseQuarterly Trade Summary & Low Risk Investment Opportunities - baoquankhu1.vn
Pulmatrix and Eos SENOLYTIX Announce $19M Merger to Advance AI-Driven Mitochondrial Therapies for Sarcopenia and Aging-Related Diseases 1 - Minichart
Pulmatrix to Merge With Eos SENOLYTIX, Rebrand on Nasdaq - tipranks.com
Pulmatrix to Merge With Eos SENOLYTIX; Raises $1M Preferred, Eos Secures Up to $18M - TradingView
Pulmatrix (PULM) plans reverse merger with Eos SENOLYTIX, legacy holders keep ~6% - Stock Titan
Finanzdaten der Pulmatrix Inc-Aktie (PULM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):